Sector News

Special Report—The top 10 cancer drug makers of 2024

November 13, 2018
Life sciences

At first glance, the list of cancer drug makers predicted to head the field by 2024 may not look so different from the list of top-selling cancer drug makers in 2017. The cast of characters is largely the same, and Roche, Celgene and Bristol-Myers Squibb—which took the top three spots last year—are projected by EvaluatePharma to rank 1-2-3 six years from now, too.

But the lists themselves don’t tell the whole story, because while Roche, Celgene and Bristol-Myers may be set to retain their top rankings, they can’t say the same for their market share.

Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boast shares within less than a percentage point of one another.

And it won’t just be the heavy hitters clawing for a piece of the pie. Last year, companies outside the top 10 grabbed just 21.5% of the market. That number is set to nearly double by 2024—swelling to 39.7%—thanks to big recent approvals for companies including Gilead Sciences, Eli Lilly, Tesaro, Clovis and more.

So what does this all mean for an already ultracompetitive lung cancer field? Things are about to get even more competitive. Read on to learn more about EvaluatePharma’s forecasts—which were generated in June 2018 and can be found at Evaluate Ltd.—and the market battles that will determine whether they become reality.

> Read the full article on the Fierce Pharma website

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 27, 2023

Positive opinion for Novo Nordisk’s Sogroya

Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.

May 27, 2023

Medtronic acquires insulin patch pump maker EOFlow for $738M amid new MiniMed rollout

Life sciences

Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.

May 27, 2023

Apnimed cracks sleep apnea puzzle, hits primary goal in phase 2 study

Life sciences

Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”

How can we help you?

We're easy to reach